ZA202304534B - Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease - Google Patents
Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's diseaseInfo
- Publication number
- ZA202304534B ZA202304534B ZA2023/04534A ZA202304534A ZA202304534B ZA 202304534 B ZA202304534 B ZA 202304534B ZA 2023/04534 A ZA2023/04534 A ZA 2023/04534A ZA 202304534 A ZA202304534 A ZA 202304534A ZA 202304534 B ZA202304534 B ZA 202304534B
- Authority
- ZA
- South Africa
- Prior art keywords
- fabry
- accompanied
- fusion protein
- preventing
- disease
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152247 | 2020-11-13 | ||
| PCT/KR2021/016630 WO2022103221A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304534B true ZA202304534B (en) | 2024-10-30 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04534A ZA202304534B (en) | 2020-11-13 | 2023-04-19 | Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (enExample) |
| EP (1) | EP4245311A4 (enExample) |
| JP (1) | JP2023549323A (enExample) |
| KR (1) | KR20220065719A (enExample) |
| CN (1) | CN116419760A (enExample) |
| AU (1) | AU2021378707A1 (enExample) |
| CA (1) | CA3196258A1 (enExample) |
| CO (1) | CO2023006437A2 (enExample) |
| IL (1) | IL302858A (enExample) |
| MX (1) | MX2023005580A (enExample) |
| WO (1) | WO2022103221A1 (enExample) |
| ZA (1) | ZA202304534B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250040515A (ko) * | 2023-09-14 | 2025-03-24 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 신규한 동결 건조 제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| RS59830B1 (sr) * | 2010-03-01 | 2020-02-28 | Bayer Healthcare Llc | Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi) |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| CA3048151A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| EP3650539A4 (en) * | 2017-07-07 | 2021-08-18 | Hanmi Pharm. Co., Ltd. | NEW THERAPEUTIC ENZYMFUSION PROTEIN AND ITS USAGE |
| FR3069340A1 (fr) * | 2017-07-21 | 2019-01-25 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| BR112020012346A2 (pt) * | 2017-12-22 | 2020-11-24 | Hanmi Pharm. Co., Ltd. | proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma |
-
2021
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230405093A1 (en) | 2023-12-21 |
| KR20220065719A (ko) | 2022-05-20 |
| CN116419760A (zh) | 2023-07-11 |
| EP4245311A4 (en) | 2024-10-30 |
| WO2022103221A1 (ko) | 2022-05-19 |
| AU2021378707A9 (en) | 2024-07-11 |
| MX2023005580A (es) | 2023-05-29 |
| AU2021378707A1 (en) | 2023-06-01 |
| CO2023006437A2 (es) | 2023-06-09 |
| JP2023549323A (ja) | 2023-11-24 |
| IL302858A (en) | 2023-07-01 |
| CA3196258A1 (en) | 2022-05-19 |
| EP4245311A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550115A1 (en) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins | |
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| SA520411662B1 (ar) | بروتينات التحام تشتمل على إنزيمات علاج بديل للإنزيم | |
| WO2018112446A3 (en) | Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease | |
| WO2003092584A3 (en) | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies | |
| MX2020008663A (es) | Anticuerpos anti-angiopoyetina-2 y usos de los mismos. | |
| EA200400518A1 (ru) | Способы лечения глазных неоваскулярных заболеваний | |
| DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
| WO2007078845A3 (en) | Systems and methods applying reversed sequence pressure to control edema flow | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MX2023004170A (es) | Compuestos y oligonucleótidos derivados de n-acetilgalactosamina (galnac). | |
| WO2000062790A3 (en) | Soluble tumor necrosis factor receptor treatment of medical disorders | |
| PH12022551598A1 (en) | Progranulin variants | |
| DE60133030D1 (de) | Erung von gelenkschmerzen und steifheit | |
| WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
| WO2022015573A3 (en) | Sars-cov-2 antigen-binding proteins and uses thereof | |
| EA200300560A1 (ru) | Улучшенный способ лечения | |
| WO2020102740A3 (en) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins | |
| MX2023005580A (es) | Uso de una proteina de fusion enzimatica terapeutica en la prevencion y el tratamiento de enfermedades renales provocadas por o acompa?adas de la enfermedad de fabry. | |
| WO2022090469A3 (en) | Ace2 fusion proteins and uses thereof | |
| MX2022010207A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o andamiaje no ig anti-adm para usarse en terapia o prevencion de choque. | |
| WO2004108885A3 (en) | Fc chimeric proteins with anti-hiv drugs | |
| MX2022003820A (es) | Metodos de tratamiento para modificar la hermodinamica. | |
| ZA202110285B (en) | Antibodies and methods of use | |
| WO2021151043A3 (en) | Methods and compositions for treating and preventing viral infection |